Clinical Specialty Index

The 2025 AHA/ACC Guideline introduces PREVENT-based CVD risk, new secondary hypertension triggers, and major changes in initial drug therapy for pharmacists managing hypertension.

CRISPR-loaded nanoparticles boost immune response against cancer.

Semaglutide shows promise in treating metabolic dysfunction-associated steatohepatitis.

The 2025 ACIP adult schedule features universal and risk-based expansions for pneumococcal, RSV, and polio vaccines, plus product, schedule, and note updates directly relevant to pharmacists.

Tenecteplase enhances late-window stroke reperfusion without added hemorrhage risk.

Semaglutide slashes kidney and heart risks in diabetes with kidney disease.

Hospital pharmacy KPIs lack validation and benchmark standards.

The 2024 KDIGO guideline for CKD introduces new recommendations for screening, diagnosis, risk stratification, pharmacologic intervention, and bone-mineral disorder, with significant implications for pharmacist monitoring roles.

Tenecteplase fails to outperform placebo in delayed stroke treatment.

Major changes in stroke risk assessment, anticoagulant preferences, and DOAC over warfarin guidance will alter daily pharmacist management of AFib patients.

Semaglutide cuts heart risks in obesity without diabetes.

Semaglutide enhances function and weight loss in obese heart failure patients.

The 2023 AGS Beers Criteria update introduces significant modifications and new recommendations impacting antihyperglycemics, anticoagulants, anticholinergics, and select drug–disease interactions for older adults.

The GOLD 2026 update brings significant changes impacting risk stratification, exacerbation management, biologics, and vaccination in COPD care.

The strength of recommendation to avoid clopidogrel in CYP2C19 intermediate metabolizers is elevated to strong, and genotype-guided antiplatelet therapy now formally extends to neurovascular indications.